Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of CytoDyn Inc. ("CytoDyn" or the "Company") (OTC: CYDY) investors concerning the Company and its officers’ possible violations of the federal securities laws.
If you suffered a loss on your CytoDyn investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/cytodyn-inc/.You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at email@example.com to learn more about your rights.
On April 27, 2020, CytoDyn issued a press release indicating it had submitted a "Biologics License Application ('BLA') to the U.S. Food and Drug Administration for Leronlimab as a combination therapy with HAART for highly treatment experienced HIV patients."
Then, on May 7, 2020, CytoDyn announced that its BLA for Leronlimab "will be considered completed after the clinical datasets are submitted on May 11, 2020."
On this news, the Company's share price fell as much as $0.225, or more than 7%, during intraday trading on May 8, 2020.
On June 30, 2020, Citron Research issued a report stating, among other things, that despite CytoDyn's "aggressively tout[ing] its investigational drug candidate, Leronlimab, as a potential treatment for COVID-19 . . . there is zero scientific data to support this view."
On this news, the Company's share price fell $3.09, or over 35%, to close at $5.68 per share on June 30, 2020, on unusually heavy trading volume.
Whistleblower Notice: Persons with non-public information regarding CytoDyn should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email firstname.lastname@example.org.
Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward-looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.